Her2/neu expression by reverse transcriptase-polymerase chain reaction in the peripheral blood of prostate cancer patients

Tumori

Volumn 93, Issue 5, 2007, Pages 467-472

  Fantinato, Ana Paula ^a,b   Tobias Machado, Marcos ^a,c   Fonseca, Fernando ^a   Pinto, Jorge Luiz Freire ^a,b   Wroclawski, Marcelo Langer ^a   Wroclawski, Eric ^a   Verotti, Maurício ^a   Del Giglio, Auro ^a,d  

^a FACULDADE DE MEDICINA DO ABC   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d NONE   (Brazil)

Author keywords

erB 2; Neoplasm circulating cells; Polymerase chain reaction; Prostatic neoplasms; Receptor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; FOLLOW UP; GLEASON SCORE; HUMAN; MALE; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 36749097296     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160709300510     Document Type: Article

References (29)

1. Grasso YZ, Gupta MK, Levin HS, Zippe CD, Klein EA: Combined nested RT-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in prostate cancer patients: correlation with pathological stage. Cancer Res, 58: 1456-1459, 1998.
2. Schmidt B, Anastasiadis AG, Seifert HH, Franke KH, Oya M, Ackermann R: Detection of circulating prostate cells during radical prostatectomy by standardized PSMA RT-PCR: association with positive lymph nodes and high malignant grade. Anticancer Res, 23: 3991-3999, 2003.
3. Seiden MV, Kantoff PW, Krithivas K, Propert K, Bryant M, Haltom E, Gaynes L, Kaplan I, Bubley G, DeWolf W: Detection of circulating tumor cells in men with localized prostate cancer. J Clin Oncol, 12: 2634-2639, 1994.
4. Tobias-Machado M, Fonseca F, Fantinato AP, Bendit I, Wroclawski ML, Wroclawski E, del Giglio A: Cytokeratin 19 expression by reverse transcriptase-polymerase chain reaction in the peripheral blood of prostate cancer patients. Tumori, 91:248-252, 2005.
5. Shariat SF, Kattan MW, Song W, Bernard D, Gottenger E, Wheeler TM, Slawin KM: Early postoperative peripheral blood reverse transcription PCR assay for prostate-specific antigen is associated with prostate cancer progression in patients undergoing radical prostatectomy. Cancer Res, 63: 5874-5878, 2003.
6. Shariat SF, Gottenger E, Nguyen C, Song W, Kattan MW, Andenoro J, Wheeler TM, Spencer DM, Slawin KM: Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy. Cancer Res, 62: 5974-5979, 2002.
7. Bianco FJ Jr, Powell IJ, Cher ML, Wood DP Jr: Presence of circulating prostate cancer cells in African American males adversely affects survival. Urol Oncol, 7: 147-152, 2002.
8. Kantoff PW, Halabi S, Farmer DA, Hayes DF, Vogelzang NA, Small EJ: Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer. J Clin Oncol, 19: 3025-3028, 2001.
9. Mejean A, Vona G, Nalpas B, Damotte D, Brousse N, Chretien Y, Dufour B, Lacour B, Brechot C, Paterlini-Brechot P: Detection of circulating prostate-derived cells in patients with prostate adenocarcinoma is an independent risk factor for tumor recurrence. J Urol, 163: 2022-2029, 2000.
10. Thiounn N, Saporta F, Flam TA, Pages F, Zerbib M, Vieillefond A, Martin E, Debre B, Chevillard S: Positive prostate-specific antigen circulating cells detected by reverse transcriptase-polymerase chain reaction does not imply the presence of prostatic micrometastases. Urology, 50: 245-250, 1997.
11. Yarden Y: Biology of HER2 and its importance in breast cancer: Oncology, 61 (Suppl 2): 1-13, 2001.
12. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med, 353: 1659-1672, 2005.
13. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 344: 783-792, 2001.
14. Ross JS, Sheehan C, Hayner-Buchan AM, Ambros RA, Kallakury BV, Kaufman R, Fisher HA, Muraca PJ: HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization. Hum Pathol, 28: 827-833, 1997.
15. Shi Y, Brands FH, Chatterjee S, Feng AC, Groshen S, Schewe J, Lieskovsky G, Cote RJ: Her-2/neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease. J Urol, 166: 1514-1519, 2001.
16. Gregory CW, Whang YE, McCall W, Fei X, Liu Y, Ponguta LA, French FS, Wilson EM, Earp HS III: Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth. Clin Cancer Res, 11: 1704-1712, 2005.
17. Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J, Sawyers CL: HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell, 6: 517-527, 2004.
18. Novaes M, Bendit I, Garicochea B, del Giglio A: Reverse transcriptase-polymerase chain reaction analysis of cytokeratin 19 expression in the peripheral blood mononuclear cells of normal female blood donors. Mol Pathol, 50: 209-211, 1997.
19. Fonseca FL, Soares HP, Manhani AR, Bendit I, Novaes M, Zatta SM, Arias V, Pinhal MA, Weinschenker P, del Giglio A: Peripheral blood c-erbB-2 expression by reverse transcriptase-polymerase chain reaction in breast cancer patients receiving chemotherapy. Clin Breast Cancer, 3: 201-205, 2002.
20. Lin YC, Chen SC, Hsueh S, Lo YF, Chow-Wu YH, Liaw IC, Cheng AJ: Lack of correlation between expression of human mammaglobin mRNA in peripheral blood and known prognostic factors for breast cancer patients. Cancer Sci, 94: 99-102, 2003.
21. Martinez-Pineiro L, Rios E, Martinez-Gomariz M, Pastor T, de CM, Picazo ML, Palacios J, Perona R: Molecular staging of prostatic cancer with RT-PCR assay for prostate-specific antigen in peripheral blood and lymph nodes: comparison with standard histological staging and immunohistochemical assessment of occult regional lymph node metastases. Eur Urol, 43: 342-350, 2003.
22. Krismann M, Todt B, Schroder J, Gareis D, Muller KM, Seeber S, Schutte J: Low specificity of cytokeratin 19 reverse transcriptase-polymerase chain reaction analyses for detection of hematogenous lung cancer dissemination. J Clin Oncol, 13: 2769-2775, 1995.
23. Lintula S, Stenman UH: The expression of prostate-specific membrane antigen in peripheral blood leukocytes. J Urol, 157: 1969-1972, 1997.
24. Ady N, Morat L, Fizazi K, Soria JC, Mathieu MC, Prapotnich D, Sabatier L, Chauveinc L: Detection of HER-2/neu-positive circulating epithelial cells in prostate cancer patients. Br J Cancer, 90: 443-448, 2004.
25. Scher HI: HER2 in prostate cancer - a viable target or innocent bystander? J Natl Cancer Inst, 92: 1866-1868, 2000.
26. Signoretti S, Montironi R, Manola J, Altimari A, Tam C, Bubley G, Balk S, Thomas G, Kaplan I, Hlatky L, Hahnfeldt P, Kantoff P, Loda M: Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst, 92: 1918-1925, 2000.
27. Ziada A, Barqawi A, Glode LM, Varella-Garcia M, Crighton F, Majeski S, Rosenblum M, Kane M, Chen L, Crawford ED: The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate, 60: 332-337, 2004.
28. Bozionellou V, Mavroudis D, Perraki M, Papadopoulos S, Apostolaki S, Stathopoulos E, Stathopoulou A, Lianidou E, Georgoulias V: Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer. Clin Cancer Res, 10: 8185-8194, 2004.
29. Spector NL, Xia W, Burris H, III, Hurwitz H, Dees EC, Dowlati A, O'Neil B, Overmoyer B, Marcom PK, Blackwell KL, Smith DA, Koch KM, Stead A, Mangum S, Ellis MJ, Liu L, Man AK, Bremer TM, Harris J, Bacus S: Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol, 23: 2502-2512, 2005.